4//SEC Filing
Poulton Stuart 4
Accession 0000950170-24-017237
CIK 0001503802other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 4:59 PM ET
Size
6.2 KB
Accession
0000950170-24-017237
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Sale
Common Stock
2024-02-15$1.33/sh−5,748$7,645→ 163,871 total - Sale
Common Stock
2024-02-15$1.40/sh−99$139→ 163,772 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001942597
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 4:59 PM ET
- Size
- 6.2 KB